Citations

Clear

3138 citation(s) found for "Smith, AM".

Consensus practice guidelines on sacroiliac joint complex pain from a multispecialty, international working group
McCormick, Zachary L. , Hurley, Robert W. , Anițescu, Magdalena , Bhaskar, Arun , Cassidy, R. Carter , Chen, Allen S. , Dawson, Timothy , Campos, José Luiz de, Hernández-Porras, Berenice Carolina , Kohan, Lynn , Reece, Ltc David E, Smith, Clark C, Stout, Alison , Szadek, Karolina M., Thomas, Donna-Ann, Tontisirin, Nuj , Vagg, Michael, Hurley, Robert W , Tontisirin, Nuj , Bhaskar, Arun, Bhatia, Anuj , Ares, Javier De Andrés , Hayek, Salim M. , Kissoon, Narayan , Elgueta Le Beuffe, María Francisca , Moon, Jee Youn , Provenzano, David , Schuster, Nathaniel M. , Smith, Clark, Zundert, Jan Van , Woodbury, Anna , Cohen, Steven P.

Mayo Clinic

Regional Anesthesia & Pain Medicine | December 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107387

10.1136/rapm-2025-107387 | PMID 41320235 Get It

Background The past two decades have witnessed tremendous growth in the appreciation and treatment of sacroiliac joint (SIJ) complex pain, including anatomical dissections that shed light on innervation, an appreciation for the contribution of extra-articular components to SIJ complex pain, the advent of radiofrequency ablation (RFA) and a host of minimally-invasive surgical techniques. Yet, there is no standardization of diagnosis and treatment paradigms. Methods In February 2023, the Boards of Directors for the American Academy of Pain Medicine (AAPM) and American Society of Regional Anesthesia & Pain Medicine (ASRA-PM) approved the development of multispecialty guidelines on SIJ complex pain. Thirty partner organizations with clinical and scientific interests in SIJ complex pain were identified, and formal letters of request-for-participation were sent to each, along with a request for nominees to serve on the committee. Twenty five organizations agreed to participate in addition to the Departments of Defense and Veterans Affairs. A steering committee developed 21 questions, which spanned criteria for diagnosis, non-interventional and interventional treatments including surgery, technical parameters on how to optimize results, and what constitutes positive outcomes. Questions were methodically assigned to specialized modules comprising 4–5 members with complementary expertise, who collaborated with the Subcommittee Lead and one of three Committee Chairs to develop preliminary drafts. Following thorough revisions, these drafts were subsequently submitted to the full committee for comprehensive review. A modified Delphi method was used in which the answers to questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was achieved. During a committee meeting before commencement, it was agreed that recommendations would be noted when there was >50% agreement among committee members, but that a formal recommendation would require ≥75% consensus. Results Twenty-one organizations formally endorsed the guidelines. The American Society of Anesthesiologists, and American Academy of Physical Medicine & Rehabilitation, and the North American Spine Society affirmed the benefit of the guidelines but did not officially endorse them. The American Academy of Neurology declined to affirm the benefit of the guidelines citing ‘lack of relevance to their membership.’ Per policies, while the Departments of Defense and Veterans Affairs did not formally review the guidelines for endorsement, their representatives approved them. In addition to being endorsed or the benefit affirmed by all voting organizations, complete consensus from committee members was obtained on all 21 questions. On two recommendations, there were dissensions from three societies who thought that selecting patients for sacral lateral branch RFA and minimally-invasive fusion should be based on ≥75% relief from two blocks instead of at least 50% relief from a single block before RFA, and greater than 50% pain relief with documented functional improvement after a single block before fusion. One additional society (Latin American Society of Regional Anesthesia) abstained on the statement that the evidence is stronger for extra-articular than intra-articular injections. The committee found that a battery of physical exam tests has reasonable sensitivity, but lower specificity, for identifying intra-articular but not extra-articular pain, with negative tests having greater predictive value than positive ones. Intra-articular injections have diagnostic validity for SIJ intra-articular, but not extra-articular, pain. There is unclear or negative evidence for imaging. The prevalence rates of intra-articular and extra-articular pathology are comparable, with both intra- and extra-articular steroid injections providing at least 4 weeks of relief in well-selected patients. However, the evidence is slightly stronger for extra-articular corticosteroid injections to provide short-term relief. The evidence base for non-interventional therapies is indirect, extrapolated mostly from low back pain studies. There is weak evidence supporting dextrose-based prolotherapy and platelet-rich plasma to provide at least 3 months of pain relief. There is strong evidence for sacral lateral branch RFA to provide relief for at least 6 months in individuals with extra-articular pathology, with face validity and indirect evidence from randomized trials supporting sacral lateral branch blocks as a prognostic tool. There is stronger evidence for larger lesions or more aggressive lesioning strategies than for less stringent techniques. There is weak evidence to support non-steroidal anti-inflammatory drugs to prevent neuritis after RFA, and in most cases anticoagulation does not require cessation in the periprocedural period. With an aggressive lesioning strategy, sensory stimulation provides minimal therapeutic benefit, with weak, extrapolated evidence that motor stimulation can provide safety benefit. The cut-off to designate diagnostic or prognostic blocks as positive is most commonly set at 50%, with higher values not shown to improve outcomes for more definitive procedures; for therapeutic treatment outcomes, the evidence supports a lower threshold of ≥30% pain relief or meaningful benefit on non-pain outcomes (eg, opioid cessation) for designation of a positive response. For carefully selected patients with intra-articular SIJ complex pain based on controlled blocks who have failed conservative therapies, there is weak or very weak evidence that minimally invasive SIJ fusion can provide benefit for at least one year. Conclusions SIJ complex pain remains an underappreciated source of chronic low back pain, affecting between 15% and 30% of patients with axial pain predominantly below L5. Answers to many questions were limited by low-quality evidence, indicating the need for better research. SIJ complex pain is a multifarious condition (ie, pain can be from different portions of both the intra- and extra-articular components of the joint) for which an interdisciplinary, multimodal treatment plan can optimize treatment outcomes.
Risk of subsequent abdominopelvic surgery in women undergoing hysterectomy with ovarian conservation: A population‐based cohort study
Ainsworth, Alessandra J. , Smith, Carin Y. , Neblett, Michael F. , Rocca, Walter A. , Laughlin‐Tommaso, Shannon K. , Khan, Zaraq , Khan, Zaraq , Cope, Adela G. , Smith, Carin Y , Laughlin-Tommaso, Shannon , Stewart, Elizabeth A.

Mayo Clinic

International Journal of Gynecology & Obstetrics | December 13, 2025 | Volume: 173 | Issue: 3 | Pages: 1433-1442

10.1002/ijgo.70745 | PMID 41386771 Get It

Abstract Objective To compare the long‐term risk of subsequent abdominopelvic surgery in women who underwent hysterectomy with ovarian conservation (H‐OC) versus referent women, and in women who underwent abdominal H‐OC versus vaginal H‐OC. Methods We conducted a population‐based cohort study in Olmsted County, Minnesota, USA including 1573 women who underwent H‐OC for a benign indication at age 18–44 years between January 1, 1980, and December 31, 2002, and 1573 age‐matched (±1 year) referent women who had not undergone hysterectomy or any oophorectomy as of the matching date. For both the H‐OC women and the referent women, we defined the index date as the H‐OC or matching date plus 6 months. The index date served as the starting point for follow‐up. Results Overall, we found an increased risk of subsequent lysis of adhesions in women who underwent H‐OC compared to referent women (hazard ratio [HR], 1.57 [95% confidence interval [CI]: 1.09–2.27]). Women undergoing H‐OC also had an increased risk of subsequent gastrointestinal tract procedures (HR, 1.18 [95% CI: 1.05–1.31]) compared to referent women. When comparing surgical route of H‐OC, we identified an increased risk of subsequent adnexal surgeries in women undergoing abdominal compared with vaginal H‐OC (HR, 1.91 [95% CI: 1.40–2.61]). Conclusion Women who underwent H‐OC have an increased risk of subsequent abdominopelvic surgeries compared to referent women. In addition, women who underwent abdominal H‐OC have an increased risk of subsequent adnexal procedures compared to women who underwent vaginal H‐OC.
(249) Challenges Affecting Compliance With Mail-in Post-vasectomy Semen Analysis in Texas
Jesus-escano, M De, Nolte, D, Helo, S, Smith, J F, Lybbert, D, Jesus-escano, M De, Nolte, D, Helo, S, Smith, J F, Lybbert, D

Mayo Clinic

The Journal of Sexual Medicine | December 9, 2025 | Volume: 22 | Issue: Supplement_4 | Pages: No page available

10.1093/jsxmed/qdaf320.245 Get It

Abstract Introduction Over 500,000 men undergo vasectomy in the U.S. annually. Although found to be 99.7% successful, the cost of vasectomy failure that results in an unplanned pregnancy far outweighs the cost of follow up semen analysis to ensure success. Despite the cost-benefits of post-vasectomy semen analysis (PVSA), compliance ranges only 30%-87%. Challenges include access to care, cost, and inconvenience of time4. Mail-in PVSA may help address these challenges and improve compliance, particularly in socially vulnerable and rural communities. Objective To examine geographic and socioeconomic community-level factors linked to mail-in PVSA completion in Texas. Methods We prospectively analyzed data from Texas men after undergoing vasectomy who received a Fellow mail-in PVSA kit between 2021–2024. Home ZIP codes were linked to the Distressed Community Index (DCI), a measure of economic well-being across US communities. The primary outcome-mail in PVSA completion within 40 weeks of being provided a test kit-was evaluated against region, DCI, and kit ordering setting. Chi-square tests and multivariable logistic regression were used, and statistical significance was assessed at the 0.05 level. Results Of 4,744 men included, 81.1% (3,849) completed mail-in PVSA testing. Compliance rates were lower among individuals living in urban areas, in the North Texas region, those residing in communities “at-risk” of socio-economic distress, and those who received their kit in a clinic (Table 1). On multivariate analysis, residence in a rural area was associated with higher completion rates (OR 1.50, 95% CI 1.12–2.04), and men who ordered their kits direct-to-consumer where significantly more likely to be compliant than those receiving their kits in a clinic (OR 10.33, 95% CI 5.01–26.26). Conclusions Men in rural areas of Texas were 74% more likely to complete mail-in PVSA, even after adjusting for social determinants of health. Direct-to-consumer users were also more likely to complete testing than clinic-ordered users. Mail-in PVSA shows higher adherence than historical clinic-affiliated methods (30–50%). Further research is needed to explore regional factors influencing completion, such as cultural attitudes, access to postal services, health literacy around male infertility, and insurance policy. In summary, mail-in PVSA testing may dramatically improve compliance for men in rural areas, and potentially decrease the risk of unplanned pregnancies. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Fellow
Rx-LLM: a benchmarking suite to evaluate safe large language model performance for medication-related tasks
Zhao, Xingmeng , Blotske, Kaitlin , Cargile, Moriah , Tilley, Adeleine , Murray, Brian , Gao, Yanjun , Henry, Kelli , Smith, Susan , Frazee, Erin N. , Bauer, Seth R. , Sohn, Sunghwan , Liu, Tianming , Cohen, Mitch , Smith, Susan E , Frazee, Erin N , Bauer, Seth R , Bennett, Tell , Cohen, Mitch , Sikora, Andrea , Henry, Kelli , Murray, Brian , Gao, Yanjun , Blotske, Kaitlin , Zhao, Xingmeng

Mayo Clinic

No container title available | December 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.01.25341004 | PMID 41404284 Get It

Abstract Background: For large language models (LLMs) to reach their potential as information technology tools that make medication use safer, clinically relevant benchmarks capable of automated grading and designed specifically to measure the performance of LLMs for medication tasks are required. The purpose of this study was to design a suite of benchmarking tests reflective of Comprehensive Medication Management (CMM; the standard of care for medication optimization) and quantify the baseline performance of the latest LLMs. Methods: We established six benchmarks representing critical stages of the CMM process: drug formulation matching, drug order (sig) generation, drug route matching, drug-drug interaction identification, renal dose identification, and drug-indication matching. For each benchmark, we curated a clinician-annotated dataset comprising 250 standardized input-output pairs including both inpatient and outpatient medications. We evaluated the clinical knowledge retrieval capabilities of three LLMs: GPT-4o-mini, MedGemma-27B, and LLaMA3-70B. We employed a zero-shot prompting strategy, excluding in-context examples, to assess the models’ internal clinical knowledge rather than their few-shot learning potential. To check reliability, each model was run three times using a temperature of 0.7 (a mid-range value of an LLM setting controlling text generation randomness). Performance was assessed using task-specific evaluation metrics including precision (positive predictive value), recall (sensitivity), F1-score, accuracy, and correctness consistency across trials. Results: Across six benchmarks, LLaMA3-70B demonstrated the highest performance in four tasks: drug-formulation matching (F1, 54.0% [95 CI: 50.1-58]), drug-order generation (accuracy, 88.0%), drug-route identification (F1, 74.3% [95 CI: 71-78]), and drug-indication identification (accuracy, 97.6% [95 CI: 95.6-99.2]). In the drug–drug interaction task, GPT-4o-mini achieved the highest overall accuracy (70.4% [95 CI: 64.8-75.7]). For renal dose–adjustment identification, GPT-4o-mini demonstrated the highest F1 score (83.3% [95 CI: 77.6-88]). Correctness-consistency scores ranged from 8.0% to 97.6% across benchmarks, with no model exhibiting uniformly superior consistency. Conclusions: Model performance varied substantially across medication-related tasks. LLaMA3-70B demonstrated promising baseline performance in tasks involving formulation, ordering, route, and indication. GPT-4o-mini showed potential advantages in drug–drug interaction detection and renal dose adjustment. These findings underscore the need for task-specific evaluation when deploying models for medication-focused clinical decision support.
Impact of High-Intensity Inspiratory Muscle Training on Inspiratory Muscle Strength in Healthy Adults
Toonstra, Amy , Smith, Joshua

Mayo Clinic

Cardiopulmonary Physical Therapy Journal | December 8, 2025 | Volume: 37 | Issue: 2 | Pages: 92-97

10.1097/cpt.0000000000000309 Get It

Background: Previous research has demonstrated that moderate-intensity inspiratory muscle training (IMT) improves inspiratory strength and exercise performance in athletes, but the impact of high-intensity IMT on inspiratory strength in healthy adults is unclear. The purpose of this study was to compare the effects of high-intensity versus moderate-intensity IMT on inspiratory strength and VO 2 peak in healthy adults. Methods: Twenty-six adults enrolled in this double-blinded randomized controlled trial. Participants completed an inspiratory strength assessment through S-Index and VO 2 peak testing before randomization into a moderate-intensity or high-intensity group. Participants in both groups performed IMT to 40 repetitions or task failure once per day, 5 times per week for 8 weeks. IMT intensity was 50% and 80% of pretraining S-Index for the moderate-intensity and high-intensity groups, respectively. S-Index and VO 2 peak testing were repeated at the end of the trial. Repeated measures ANOVA were used to assess differences of pretraining and post-training S-Index and VO 2 peak between groups. Results: A significant increase in mean (SD) S-Index from pretraining to post-training was present for both moderate-intensity (7.6% (8.9), P = .001) and high-intensity (10.8% (11.7), P < .001) groups. No significant group ( P = .88) or interaction ( P = .44) effects existed for S-Index. There were no significant main effects for group, time, or interaction for VO 2 peak ( P > .05 for all). Conclusions: Both moderate-intensity and high-intensity IMT to task failure in healthy adults led to significant improvements in inspiratory strength. No effects were observed in either group on changes in VO 2 peak. Given that moderate-intensity and high-intensity IMT to task failure were both effective at improving inspiratory strength in healthy adults, training intensity at less intense, moderate levels can be used to achieve similar strength gains.
Drug-drug interaction identification using large language models
Blotske, Kaitlin , Zhao, Xingmeng , Henry, Kelli , Gao, Yanjun , Tilley, Adeleine, Cargile, Moriah, Murray, Brian , Smith, Susan , Frazee, Erin N. , Bauer, Seth R. , Sohn, Sunghwan , Liu, Tianming , Cohen, Mitch , Zhou, Hongjian , Clifton, David A. , Smith, Susan E , Frazee, Erin N , Bauer, Seth R , Bennett, Tell , Cohen, Mitch , Sikora, Andrea , Henry, Kelli , Murray, Brian , Gao, Yanjun , Blotske, Kaitlin , Zhao, Xingmeng , Tilley, Adeleine, Cargile, Moriah, Sohn, Sunghwan , Liu, Tianming , Zhou, Hongjian , Liu, Fenglin , Clifton, David A.

Mayo Clinic

No container title available | December 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.03.25341549 | PMID 41503479 Get It

Abstract Background The purpose of this study was to develop a series of benchmarks specifically for large language model (LLM) performance in the identification of drug-drug interactions (DDIs). Methods We evaluated six LLMs using a clinician-designed dataset of 750 DDI scenarios. Tasks included: (1) a pointwise two-drug classification task (2) a pairwise three-drug discrimination task and (3) a listwise 4–6 drug selection task. Zero-shot prompting was applied and performance was assessed using precision, recall, F1 score, accuracy, and self-consistency. Results Model performance varied by task structure and interaction severity. GPT-5-Chat demonstrated the highest recall and F1 score in the pointwise task (80.7% and 80.2%), whereas DrugGPT achieved superior accuracy in the pairwise (93.7%) and listwise task (92.6%). All models had improved performance with more severe compared to less severe DDIs (accuracy 72.0-99.2% vs. 58.3-86.7%). All models tended to have higher self-consistency in the pairwise and listwise experiments compared to the pointwise experiment (68.8-93.6% vs. 31.0-74.2%). No model exhibited uniformly high reliability across all tasks. Conclusions Current LLMs show inconsistent capabilities in identifying DDIs. Performance degrades as reasoning space expands with limited stability. These findings emphasize the need for multi-format evaluation frameworks and reliability-aware assessment when considering LLMs for medication-safety applications.
Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
Beck, Roy W. , Hirsch, Irl B., Raghinaru, Dan, Lum, John W. , Pinsker, Jordan E. , Kudva, Yogish C. , Group*, 2IQP Study, Desjardins, Donna, Kurek, Corey, Kaur, Ravinder Jeet , Livingood, Daine, Rizvi, Shafaq , Graham, Timothy E., Terry, Adrienne, Luker, Ryan, Mellenthin, Melanie, Rezac, Stephanie, Liljenquist, David R., Rogers, Justin, Williams, Jonathan, Christensen, Rochelle, Lee, In‐Kyoung, Malone, Joann, Spanakis, Elias K. , Singh, Lakshmi G., Churchill, Jade, Comen, Kathleen, Scott, William H., Davis, Georgia M. , Arroyo, Lizda Guerrero, Oladejo, Omolade , Usman, Sabeena, Ahmann, Andrew , Schmid, Caleb, Dean, Ariel, Branigan, Deborah , Caswell, Brittany, Heyerman, Tess, Tessman, Brian, Vanderheide, Jnh, Dennis, Brittany , Hendricks, Lisa, Reyes-Rodriguez, Clemente, Wolf, Valerie, Coyne, Kasey, Kravarusic, Jelena, Fronczyk, Evelyn, Herrmann, Stefanie, Penn, Samsam C., Blevins, Thomas , Casaubon, Luis, Espinosa, Valerie, Pandit, Keta, Perez, Jennifer, Stewart, Ana, Assir, Courtney, Fields, Cory, Kruger, Davida , Estrada, Kathleen, Jones, J. Kimberly, Mukhashen, Shereen, Corker, Natalie, Hunter, Heather, Layton, Paula, Brown, Sue A. , Afreen, Samina , Dhillon, Jasmeen, Emory, Emma, Fulkerson, David, Fuller, Morgan, Holmes, Viola, Kollar, Laura, Toole, Elyse, Levister, Camilla, O’Malley, Grenye , Ipek, Aslihan, Alabi, Denise, Ellis, Emily, Hassan, Shaziah, Ogyaadu, Selassie, Tamarez, Denisa, Weinstock, Ruth S. , Stone, Sheri , Bzdick, Suzan, Agostini, Lynn, Bulger, Jane , Wolpert, Howard , Atakov-Castillo, Astrid , Sullivan, Asya, Aia, Corinne, Brouillard, Elizabeth, Driscoll, Marsha, Lapier, Heather, Payra, Sherryl, Vancer, Louise, Averkiou, Xenia, Baran, Jesica, Holod, Rosanna, Litvicov, Patrisia, Mandava, Patali, Swinton, Sydney, Khakpour, Dori , Broyles, Frances E. , Marks, Sheryl, Mitchell, Tina, Hairston, Babette, Costello, Reilly, Curtis, Stella, Kamimoto, Jorge Jo, Peleckis, Amy J. , Sultan, Rahaf , Dalton-Bakes, Cornelia, Bourne, Patricia, Haidar, Ahmad, Pasqua, Melissa, Tardio, Vanessa , Moore, Adelyn, Kemp, Gabrielle, Raskin, Philip, Jordan, L.F., Shao, Baomei, DoNguyen, Trang, Meeks, Tram, Phan, Michael , Lesniak, Amanda, Becerra, Mario, Bellini, Natalie J. , Denallo, Erica, Lewis, Claudia , Tribout, Jerry, Tribout, Megan, DiFrancesco, Kathryn, Phillips, Kylie, Raghinaru, Dan, Campos, Tiffany, Morrell, Beth, Oduah, Vanessa, Cardenas-Villamil, Gabriela, Morales, Amanda, Murphy, Carlos, Strayer, Heidi, Spanbauer, Charles , Kollman, Craig, Sasson-Katchalski, Ravid, Piquette, Nicole, Wheatcroft, Alex, WHITE, KIRSTIN N., Carmelo, KC, Janicek, Robert, Gabrielson, Deanna, Mercado, Kevin, Beck, Roy W , Group*, 2IQP Study, Smith, Joshua W. , Christensen, Rochelle, Malone, Joann, Pasquel, Francisco J. , Tajrishi, Farbod Zahedi , Arroyo, Lizda Guerrero, Dean, Ariel, Howard, Matthew, Vander-Heide, Jesse, Ahn, David , Aleppo, Grazia , Fields, Cory, Layton, Paula, Oliveri, Mary Clancy , Levy, Carol J. , Agostini, Lynn, Steenkamp, Devin W , Spaic, Tamara , Liu, Selina , Marks, Sheryl, Mitchell, Tina, Costello, Reilly, Curtis, Stella, Rickels, Michael R. , Bourne, Patricia, Tsoukas, Michael A. , Pasqua, Melissa-Rosina , Moore, Adelyn, Kemp, Gabrielle, Meeks, Tram, Phan, Michael, Hatipoğlu, Betül , Lesniak, Amanda, Howard, Quiana , DiFrancesco, Kathryn, Raghinaru, Dan, Morrell, Beth, Morales, Amanda, Kanapka, Lauren , Le, Van

Mayo Clinic

Diabetes Care | December 5, 2025 | Volume: 49 | Issue: 2 | Pages: e18-e20

10.2337/dc25-2059 | PMID 41348329 Get It

Intravenously administered LV-169 delivers a functional BCMA-CAR transgene to niche-resident T cells and leads to elimination of disseminated myeloma in MHC-deficient NSG mice
Nenavath, Gopal Naik, Gazi, Md Yeashin, Hawkes, Aaron, Gwilt, Collin, Chin, Chia-Hsuan , Kinney, Christian, Salimi, Hamid , Suwanmanee, Thipparat, Phung, Darren, Briercheck, Edward L. , Smith, Eric L. , Lin, Yi , Peng, Kah-Whye , Packiriswamy, Nandakumar , Carey, Timothy S. , Phung, Darren, Krotova, Karina Y. , Vandergaast, Rianna , Venugopal, Kartika , Smith, Eric

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5896-5896

10.1182/blood-2025-5896 Get It

Abstract Chimeric Antigen Receptor (CAR) T cell therapy is a transformative treatment for hematologic malignancies. However, ex vivo autologous CAR T cell manufacturing presents substantial logistical and clinical challenges. Direct in vivo CAR-T cell engineering offers a new paradigm for CAR T delivery. We recently developed the CD3-targeted lentiviral vector LV-169 which can deliver a CAR transgene to resting niche-resident T cells in lymphoid tissues. LV169 is pseudotyped with a mix of chimeric and nonchimeric VSV-G proteins detargeted (blinded) from the natural LDL receptor and re-targeted to T cells through the display of a CD3-specific scFv. Here we demonstrate that LV169 can specifically deliver a functional aBCMA-CAR transgene to resting human T cells in PBMC cultures from the healthy volunteers and from multiple myeloma patients. For clinical translation, we selected an αBCMA-CAR construct comprising a fully human single heavy chain nanobody linked to 41BB and CD3z cytoplasmic signaling domains. Human T cells expressing this CAR construct have low tonic signaling and efficiently kill BCMA-positive myeloma target cells with similar or lower associated cytokine release compared to a clinically relevant benchmark BCMA-CAR. To further improve LV169 and to minimize CAR protein incorporation in the LV envelope which may lead undesirably to myeloma cell transduction, we placed the CAR transgene under a T-cell specific Lck promoter in reverse orientation relative to the 5' LTR. The transcriptional activity of the Lck promoter was comparable to that of a constitutive EF1a promoter in primary T cells and, in contrast to EF1a had minimal activity in a variety of other tested cell types including the HEK293T producer cell line and the THP-1 monocytic cell line. Western blotting confirmed the absence of CAR protein in LV particles (LVP) generated using the Lck promoter-driven reverse orientation construct. In contrast, high levels of CAR protein were detected in LVP generated using the parental EF1a promoter-driven construct. The LV-incorporated CAR protein mediated off-target gene delivery to BCMA-positive myeloma cells. The therapeutic efficacy of intravenously administered LV169 LV particles carrying BCMA-CAR constructs was tested in the OPM-2 human multiple myeloma xenograft model. NSG mice with knockout of MHC-I and MHC-II, and with advanced disseminated OPM-2-Luc tumors were engrafted with human PBMC one week prior to intravenous LV169-BCMA-CAR administration. Mice were treated with single intravenous injection of LV169 at different doses 3 weeks after tumor engraftment. OPM-2-Luc tumor burden was monitored by regular luciferase imaging. All treated mice cleared their tumors within 28-days following LV administration and the rate of clearance was correlated to the LV particle dose. Even at the 4e8 dose level (by p24) tumors were completely cleared. Eighty four days post-treatment the treated mice remained tumor-free and resisted re-challenge with OPM-2 tumor cells. Circulating CAR-T cells, monitored by flow cytometry, became detectable by 14 dpi and peaked between 21-35 dpi. Following tumor clearance, the number of circulating CAR-T cells declined dramatically. The treatment was well tolerated and analysis of cytokines associated with CAR-T cell cytotoxicity confirmed the absence of a severe cytokine storm. IFNγ was the only cytokine which was elevated during the expansion period of CAR-T cells, while IL-2, IL-6, TNFα and GM-CSF were barely detectable. In summary the characteristics of our new developed LV169-based platform make it suitable for further clinical translation which is underway.
Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma
Smith, Stephen D. , Giri, Sharmila, Tatoian, Emily Tamar, Grossfeld, Trenton, Lynch, Ryan C. , Nowakowski, Grzegorz S. , Sundaram, Suchitra , Ness, Andy , Wang, Yucai , Pang, Yifan , Gopal, Ajay K. , Warren, Edus Houston , Park, Steven

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3575-3575

10.1182/blood-2025-3575 Get It

Abstract Introduction: First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. Multitargeted combinations, including optimized chemotherapy with novel agents targeted to MCL, may best address the biologic heterogeneity of this disease. Building on prior experience using modified VR-CAP and R-cytarabine, we enhanced this regimen by adding acalabrutinib while reducing cytarabine, aiming for improved efficacy and safety without impeding stem cell collection. To evaluate this regimen, we conducted a phase 2 multicenter trial at four centers in the Academic and Community Cancer Research United (ACCRU) network. Methods: CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. Eligible patients (pts) were at least 18 years old with adequate organ function, measurable disease, no CNS involvement; and were ASCT-eligible per investigator. VR-CAP (cycles 1, 3, and 5) employed bortezomib 1.3 mg/m² subcutaneously days 1,8, and 15; rituximab 375 mg/m² day 1; cyclophosphamide 750 mg/m² day 1; doxorubicin 50 mg/m2 day 1; and prednisone 100 mg PO days 1-5. Cycles 2,4, and 6 used outpatient rituximab with cytarabine at 3 g/m² x 2 daily doses in the first 5 pts, after which the dose was reduced to 2 gm/m2 x 2 daily doses due to thrombocytopenia. Acalabrutinib 100 mg p.o. twice daily was given continuously but held for grade 4 thrombocytopenia or clinically significant toxicity. Growth factors and prophylactic antimicrobials were required. Responses were assessed after six cycles using FDG PET/CT, bone marrow aspirate/biopsy (BM Bx), and endoscopy when indicated (Lugano 2014). The primary endpoint was complete metabolic response (CMR) rate at end of treatment (EOT). Secondary endpoints included safety, feasibility of stem cell collection, proportion proceeding to ASCT, and progression-free (PFS) and overall survival (OS). Peripheral blood measurable residual disease (MRD) was evaluated using the ClonoSEQ assay (Adaptive Biotechnologies). A Simon two-stage design was used, targeting a CMR rate ≥ 70% versus a null rate of 50%, with a total sample size of 39 evaluable pts. Results: 41 pts were accrued from October 2021 through May 2025, 37 of whom completed all 6 cycles and are evaluable for response; two are still on therapy, and two discontinued therapy early for toxicity. Median age was 63 years (range 41-73), 22% were female, and 85% were White. MIPI risk groups were low (44%), intermediate (39%), and high (17%), and Ki-67 was ≥ 30% in 54% of pts. Three pts (7%) had known TP53 mutations by sequencing. At EOT, the CMR rate was 85.3% among all pts (35/41; 95% CI 67.9%-92.9%), or 94.5% among evaluable pts (35/37). BM Bx was performed in 31 pts at EOT, 30 of which (96.8%) were negative for MCL. Undetectable peripheral blood MRD using a 10^6 threshold (uMRD6) was achieved at EOT in 78.1% (25/32) of tested pts, and 93.8% (30/32) achieved uMRD5. Nine of 41 pts underwent ASCT; no patient failed stem cell collection. Maintenance therapy was not protocol-defined but included rituximab in 91.9% of pts and a BTK inhibitor in 21.6% of pts. With a median follow-up of 16.7 months, PFS and OS rates at 18 months were 76.7% (95% CI: 60.7%-96.9%) and 95.5% (95% CI: 87.1%-100%). Toxicities were primarily hematologic. Grade 3+ toxicities included thrombocytopenia (66.6%), neutropenia (28.2%), and anemia (25.6%). Grade 3+ febrile neutropenia was observed in 10.2% of pts. Peripheral neuropathy was seen in 20.5% of pts and all grade 1-2. Bleeding events included purpura in 2 pts (5.2%) and epistaxis in 1 patient (2.6%). One case of atrial fibrillation was observed. Eighteen pts required temporary dose hold of acalabrutinib for toxicity (mainly thrombocytopenia), and 2 had acalabrutinib dose reductions. Serious adverse events occurred in 6 pts, and no treatment-related deaths occurred. Conclusions: CARiBOU is an efficient, highly effective outpatient regimen for 1st line MCL, employing intermediate dose cytarabine with continuous acalabrutinib. With supportive care and platelet monitoring, this approach safely yielded high rates of CMR and uMRD6, supporting multitargeted induction therapy for appropriate pts with untreated MCL.
Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium
Iqbal, Umar , Vale, Colin , Smith, Kinaya, Waller, Allyson, McCormick, Benjamin J. , Zhang, Ling , Shukla, Asmita, Yang, Jay , Dailey-Hansen, Amanda, Tantravahi, Srinivas K. , Oehler, Vivian G. , Radich, Jerald P. , Nai, Nhi , Foucar, Charles , Pinilla‐Ibarz, Javier , Deininger, Michael W. , Sweet, Kendra , Jain, Akriti Gupta , Iqbal, Umar, Hunter, Anthony M. , Wei, Wei , Handa, Shivani , Mims, Alice S , Crane, Genevieve M. , Raychaudhuri, Suravi , Smith, B. Douglas , Chan, Onyee , Badar, Talha , Mukherjee, Sudipto , Atallah, Ehab , Xie, Zhuoer

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 904-904

10.1182/blood-2025-904 Get It

Abstract Introduction: Despite advent of multiple tyrosine kinase inhibitors (TKIs) and newer treatment methods for AML and ALL, the outcomes of patients (pts) with chronic myeloid leukemia in blast phase (CML-BP) remain poor. Consensus guidelines on treatment of CML-BP are scarce. A recent study from the European leukemia network blast phase registry on 240 pts reported marked heterogeneity in treatment patterns and lack of an accepted standard. Hence, we undertook this study through the H Jean Khoury Cure CML Consortium (HJKC3) to describe the treatment patterns and outcomes of pts with CML-BP in the US. Methods: This is a multi-institution, retrospective study. IRB approval was obtained at each institution and data sharing agreements were executed. All pts diagnosed with CML-BP based on modified MD Anderson Criteria (≥30% blasts in the blood or bone marrow or extramedullary (EM) disease) from 2010 to 2025 were included. Categorical variables were compared using Chi-square test. Overall survival (OS) was calculated from time of diagnosis of CML BP to death from any cause. Event free survival (EFS) was calculated from date of best response to event (death or relapse). Results: Of the 283 pts with CML-BP, 96 (33.9%) were female and 187 (66.1%) were males. At the time of diagnosis, 183 (64.6%) had CML-CP, 21 (7.4%) pts had CML-AP and 79 (27.9%) pts had de-novo CML-BP. For the 204 pts that were initially diagnosed with CML-CP or CML-AP, the median time to progression to CML-BP was 22.5 months (1-207 months). Median age at diagnosis of CML-BP was 50 years (range 16-86 years). EM disease was present in 78 (27.6%) pts (38 myeloid sarcoma, 30 central nervous system and 10 skin). Blasts were of myeloid phenotype in 168 (59.4%), lymphoid in 103 (36.4%) and mixed in 9 (3.2%) pts. The bcr-abl protein was p210 in 229 (80.9%), p190 in 8 (2.8%) and p230 in 2 (0.7%) pts. ABL kinase domain mutation was seen in 42.1% (80/190) pts, with T315I being the most common (n=32), followed by E255K (n=16). Next generation sequencing was performed in 117 pts. The most common mutations were ASXL1 (n=27), RUNX1 (n=14), BCOR (n=4), DNMT3A (n=4) and BCORL1 (n=3). Of the 283 pts, 269 underwent CML-BP directed therapy. 63 (23.4%) pts were treated with TKI monotherapy, 184 (68.4%) pts were treated with a combination of chemotherapy (chemo) and TKI and 22 (8.2%) pts were treated with chemo alone. Response rate after CML-BP directed therapy was 75.3% (n=213). Best response was return to CML-CP in 49 pts, CHR with PCyR in 18 pts, CCyR in 31 pts, MMR in 31 pts, MR4 in 18 pts, MR4.5 in 19 pts and MR5 in 47 pts. Rate of response with 2G and ponatinib was significantly better than imatinib (85.3% and 77.3% vs 63.6%; p=0.04). 149 (55.4%) pts proceeded to alloSCT. Of the 213 pts that responded, 59 (27.7%) relapsed. At a median follow-up of 47 months, the median OS for all pts was 19.7 months (95% CI: 16.3-40.2 months), with 5-year OS rate of 38% (95% CI: 32-45%). Pts with myeloid phenotype had a significantly lower OS compared to lymphoid and mixed phenotype (Median OS 14.9 vs 45.9 and 31.1 months respectively; p=0.02). OS of pts that were treated with a combination of TKI and chemo was significantly longer compared to pts treated with TKI or chemo alone (52.9 vs 16.1 or 7.5 months; p&lt;0.0001). Dasatinib (n=99; 34.9%) and ponatinib (n=97; 34.3%) were the most used TKIs followed by imatinib (n=23; 8.1%), nilotinib (n=21; 7.4%), bosutinib (n=8; 2.8%) and asciminib (n=3; 1.1%). Pts treated with ponatinib had a numerically longer OS compared to 2G-TKI and imatinib, however this was not statistically significant (40.1 vs 30.6 and 20.3 months; p=0.52). EFS for pts treated with ponatinib was significantly longer compared to 2G-TKI or imatinib (25.9 vs 17.6 and 15.9 months; p=0.03). In a landmark analysis, pts that underwent alloSCT within 6 months of diagnosis had a significantly longer OS compared to those who did not (69.3 vs 16.0 months; p=0.006). Conclusion: CML-BP continues to have poor prognosis. Treatment is heterogenous involving various combinations of TKI and chemo. In our analysis, treatment with 2G-TKI or ponatinib led to better responses. CML-BP with myeloid phenotype had worse OS. Treatment with ponatinib was associated with a numerically longer OS and significantly longer EFS compared to 2G-TKI and imatinib. In addition, treatment with chemo in combination with TKI and alloSCT led to improved OS.